Development of KiBank, a database supporting structure-based drug design

KiBank is a database of inhibition constant (Ki) values with 3D structures of target proteins and chemicals. Ki values were accumulated from peer-reviewed literature searched via PubMed. The 3D structure files of target proteins were originally from Protein Data Bank (PDB), while the 2D structure files of the chemicals were collected together with the Ki values and then converted into 3D ones. In KiBank, the chemical and protein 3D structures with hydrogen atoms were optimized by energy minimization and stored in MDL MOL and PDB format, respectively. KiBank is designed to support structure-based drug design. It provides structure files of proteins and chemicals ready for use in virtual screening through automated docking methods, while the Ki values can be applied for tests of docking/scoring combinations, program parameter settings, and calibration of empirical scoring functions. Additionally, the chemical structures and corresponding Ki values in KiBank are useful for lead optimization based on quantitative structure-activity relationship (QSAR) techniques. KiBank is updated on a daily basis and is freely available at . As of August 2004, KiBank contains 8000 Ki values, over 6000 chemicals and 166 proteins covering the subtypes of receptors and enzymes.

[1]  Alexander E. Kel,et al.  TRANSFAC®: transcriptional regulation, from patterns to profiles , 2003, Nucleic Acids Res..

[2]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[3]  Ferran Sanz,et al.  3D-QSAR methods on the basis of ligand–receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands , 2000, J. Comput. Aided Mol. Des..

[4]  B. Roth,et al.  The Multiplicity of Serotonin Receptors: Uselessly Diverse Molecules or an Embarrassment of Riches? , 2000 .

[5]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[6]  A. Anderson.  The process of structure-based drug design. , 2003, Chemistry & biology.

[7]  Wolfgang Sippl,et al.  Development of biologically active compounds by combining 3D QSAR and structure-based design methods , 2002, J. Comput. Aided Mol. Des..

[8]  A J Cuticchia,et al.  Future vision of the GDB Human Genome Database , 2000, Human mutation.

[9]  Miki Akamatsu,et al.  Current state and perspectives of 3D-QSAR. , 2002, Current topics in medicinal chemistry.

[10]  Glen E Kellogg,et al.  3D QSAR in modern drug design. , 2003, EXS.

[11]  Kaori Fukuzawa,et al.  Fragment molecular orbital method: use of approximate electrostatic potential , 2002 .

[12]  Susumu Goto,et al.  The KEGG databases at GenomeNet , 2002, Nucleic Acids Res..

[13]  K. Nakata.  Theoretical approach to endocrine disruptors. , 2002, Frontiers in bioscience : a journal and virtual library.

[14]  X. Chen,et al.  TTD: Therapeutic Target Database , 2002, Nucleic Acids Res..

[15]  H J Böhm,et al.  Computational tools for structure-based ligand design. , 1996, Progress in biophysics and molecular biology.

[16]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[17]  Philip M Dean,et al.  De novo drug design: integration of structure-based and ligand-based methods. , 2004, Current opinion in drug discovery & development.

[18]  S. Kim,et al.  The conformation and activity relationship of benzofuran type of angiotensin II receptor antagonists. , 2000, Bioorganic & medicinal chemistry.

[19]  H. Villar,et al.  Strategies for Indirect Computer-Aided Drug Design , 1993, Pharmaceutical Research.

[20]  Peter B. McGarvey,et al.  PIR: a new resource for bioinformatics , 2000, Bioinform..

[21]  C. Lipinski.  Drug-like properties and the causes of poor solubility and poor permeability. , 2000, Journal of pharmacological and toxicological methods.

[22]  C. Selassie,et al.  QSAR: then and now. , 2002, Current topics in medicinal chemistry.

[23]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2004, Nucleic Acids Res..

[24]  D. Kirkpatrick,et al.  Structure-based drug design: combinatorial chemistry and molecular modeling. , 1999, Combinatorial chemistry & high throughput screening.

[25]  Kotoko Nakata,et al.  Development of the receptor database (RDB): application to the endocrine disruptor problem , 1999, Bioinform..

[26]  D S Goodsell,et al.  Automated docking of flexible ligands: Applications of autodock , 1996, Journal of molecular recognition : JMR.

[27]  H McIlwain.  The origin and use of the terms competitive and non-competitive in interactions among chemical substances in biological systems. , 1986, Essays in biochemistry.

[28]  Larry R. McLean,et al.  Evaluation of proposed modes of binding of (2S)-2-[4-[[(3S)-1-acetimidoyl-3-pyrrolidinyl]oxy]phenyl]-3-(7-amidino-2-naphthyl)propanoic acid hydrochloride and some analogs to Factor Xa using a comparative molecular field analysis , 1998, J. Comput. Aided Mol. Des..

[29]  Yutaka Akiyama,et al.  Fragment molecular orbital method: application to polypeptides , 2000 .

[30]  Yuichi Harano,et al.  Complete protein structure determination using backbone residual dipolar couplings and sidechain rotamer prediction , 2004, Journal of Structural and Functional Genomics.

[31]  賢司 小野寺,et al.  KiBank:創薬のためのタンパク質—化合物相互作用解析支援データベース , 2004 .

[32]  Yuichi Inadomi,et al.  PEACH 4 with ABINIT-MP: a general platform for classical and quantum simulations of biological molecules. , 2004, Computational biology and chemistry.

[33]  Maria Jesus Martin,et al.  The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003 , 2003, Nucleic Acids Res..

[34]  D. Bailey,et al.  High-throughput chemistry and structure-based design: survival of the smartest. , 2001, Drug discovery today.

[35]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[36]  Todd J. A. Ewing,et al.  DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases , 2001, J. Comput. Aided Mol. Des..

[37]  Gisbert Schneider,et al.  Virtual screening and fast automated docking methods. , 2002, Drug discovery today.

[38]  Gerhard Klebe,et al.  Recent developments in structure-based drug design , 2000, Journal of Molecular Medicine.

[39]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[40]  Wolfgang Sippl,et al.  Binding affinity prediction of novel estrogen receptor ligands using receptor-based 3-D QSAR methods. , 2002, Bioorganic & medicinal chemistry.

[41]  Kaori Fukuzawa,et al.  Fragment molecular orbital study of the binding energy of ligands to the estrogen receptor , 2003 .